Möchten Sie immer auf dem neuesten Stand bleiben?

Phase 2b to assess efficacy, safety, and immunogenicity2,850 participants to be enrolled across European countries  Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical...

Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836  Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing...

Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profileRobust complementary immune responses were...

Pneumagen’s intranasal broad-spectrum antiviral therapy reduced infection, improved symptoms and severity and reduced viral load in a Phase II influenza study in data published in the high-impact,...

OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of...

Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory...

PDSB announced that Infectimune® immune response data were featured at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting.

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial...

PDS Biotech announced that immune response data with a novel Infectimune® based flu vaccine will be featured at the IMMUNOLOGY2025 Annual Meeting.

JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient...